Authors
Yilin Ye, Lianxin Zhu, Cui Chen, Peng Sun, Zhihua Zhu
Published in
JNCI cancer spectrum. Nov 17, 2026. Epub Nov 17, 2026.
Abstract
Distant-stage incidence and cancer-specific mortality describe different aspects of cancer burden. We compared their long-term population trends across 10 solid cancers in the United States.
Age-adjusted distant-stage incidence from the Surveillance, Epidemiology, and End Results (SEER) Program 17 Registries database (SEER17) and national cancer-specific mortality were analyzed for 2004-2023 using Joinpoint regression. Primary incidence models omitted 2020; mortality models retained 2020. Both endpoints were also analyzed over a common 2004-2019 window. Endpoint direction was defined from the 95% confidence interval for average annual percentage change (AAPC). Relative survival and incidence-based mortality were complementary analyses.
Among 5,545,600 incident cancers, 1,060,790 were diagnosed at distant stage. Breast cancer, prostate cancer, and melanoma had increasing distant-stage incidence with declining mortality; lung and colorectal cancers declined in both endpoints; pancreatic, liver and intrahepatic bile duct, and uterine cancers increased in both; and kidney and renal pelvis and stomach cancers had no clear incidence change with declining mortality. All 10 paired patterns were unchanged in the common 2004-2019 window. One- and 3-year distant-stage relative survival increased for all cancers, and all 20 primary survival contrasts remained significant after Benjamini-Hochberg adjustment.
The relation between distant-stage incidence and cancer-specific mortality differed by cancer site and was unchanged in a common pre-pandemic window. Distant-stage incidence is best interpreted alongside, rather than as a substitute for, population mortality.
PMID:
43046609
Bibliographic data and abstract were imported from PubMed on 18 Nov 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 3
- Comments 0